

Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial

Upon the original publication of this article [Merat S. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial. *Clin Infect Dis* 2020;70(10):2206–2212. <https://doi.org/10.1093/cid/ciz628>], the members of SD1000 research

team as shown in the Appendix were not correctly tagged with their affiliations under the SD1000 Research Team contributor group.

The details have been corrected only in this erratum (as shown below) to preserve the published version of record. The publisher regrets this error.

SD1000 Research Team Contributor Group:

Shahin Merat; SD1000 Research Group

Shahin Merat,¹ Amir-Houshang Sharifi,¹ Hossein Poustchi,¹ Eskandar Hajiani,² Abdolsamad Gharavi,¹ Jalal Karimi,³ Fariborz Mansour-Ghanaei,⁴ Mohammad-Reza Fattahi,⁵ Lida Ahmadi,⁵ Mohammad-Hossein Somi,⁶ Hamid Kalantari,⁷ Mohammad-Reza Ghadir,⁸ Farshad Sheikhesmaeili,⁹ Nadiéh Baniasadi,¹⁰ Masoudreza Sohrabi,¹¹ Seyedhamid Moosavy,¹² Masood Ziaee,¹³ Mohammad-Javad Zahedi,¹⁴ Marjan Mokhtare,¹⁵ Shahnaz Sali,¹⁶ Babak Sayad,¹⁷ Behrooz Afshar,¹⁸ Alireza Bakhshpour,¹⁹ Abazar Parsi,² Afsaneh Sharifian,²⁰ Taghi Amiriani,²¹ Zeinab Malekzadeh,¹ Dorsa Merat,¹ Azita Ganji,²² Fereidoun Rahmani-Samani,²³ Raika Jamali,¹ Masoomeh Sofiani,²⁴ Mohammad Ghezlou,²⁵ Amir Ali Sohrabpour,¹ Ladan Goshayeshi,²² Seyed-Mohammad Valizadeh-Toosi,²⁶ Layli Eslami,¹ Iraj Maleki,²⁶ Ahmad Hormati,⁸ Ali-Akbar Shayesteh,² Elahe Shayesteh,² Alireza Norouzi,²² Zahra Abna,²⁷ Alireza Janbakhsh,²⁸ Hafez Fakheri,²⁶ Mohammad Minakari,²⁹ Hossein Sardarian,³⁰ Adel F Allah Ghajary,³¹ Mojtaba Fattahi-Abdizadeh,³² Maryam Latifnia,³³ Fatemeh Roozbeh,³⁴ Shahram Agah,¹⁵ Saba Fakhrieh-Asl,⁴ Alireza Nateghi-Baygi,¹ Babak Fattahi,¹ Helia Nateghi-Baygi,¹ Andrew Hill,³⁵ and Reza Malekzadeh¹

¹Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, ²Alimentary Tract Research Center, School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, ³Department of Infectious Diseases and Tropical Medicine, Fasa University of Medical Sciences, ⁴Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, ⁵Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, ⁶Tabriz University of Medical Sciences, ⁷Isfahan Liver Disease Research Center, Isfahan University of Medical Sciences, ⁸Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, ⁹Liver and Digestive Research Center, Kurdistan University of Medical Sciences, Sanandaj, ¹⁰Bam University of Medical Sciences, ¹¹Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, ¹²Hormozgan University of Medical Science, Bandarabbas, Iran, ¹³Infectious Diseases Research Center, Birjand University of Medical Sciences, ¹⁴Gastroenterology and Hepatology Research Center, Kerman University of Medical Sciences, ¹⁵Colorectal Research Center, Iran University of Medical Science, and ¹⁶Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, ¹⁷Infectious Diseases Research Center, Kermanshah University of Medical Sciences, ¹⁸Hamadan University of Medical Sciences, ¹⁹Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, ²⁰Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, ²¹Golestan Research Center for Gastroenterology and Hepatology, Golestan University of Medical Science, Gorgan, ²²Department of Gastroenterology and Hepatology, Mashhad University of Medical Sciences, ²³Shahrekord University of Medical Sciences, ²⁴Infectious Disease Research Center, Arak University of Medical Science, ²⁵Gastroenterology and Hepatology Disease Research Center, Arak Medical Science University, ²⁶Gut and Liver Research Center, Mazandaran University Of Medical Sciences, Sari, ²⁷Sirjan University of Medical Sciences, ²⁸Infectious Diseases Department, Kermanshah University of Medical Sciences, ²⁹Isfahan University of Medical Sciences, ³⁰Guilan University of Medical Science, Bandar Anzali, ³¹Chamran Hospital of Saveh, ³²Department of Microbiology, and ³³Department of Gastroenterology and Hepatology, Sabzevar University of Medical Sciences, and ³⁴Mazandaran University of Medical Sciences, Sari, Iran; and ³⁵Department of Translational Medicine, University of Liverpool, United Kingdom.

DOI: 10.1093/cid/ciaa1768

Corrigendum to: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis

After the first publication of this guideline [Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical Practice Guidelines by the

Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. *Clin Infect Dis* 2021;72(2):e49–e88, <https://doi.org/10.1093/cid/ciaa1216>], the authors have updated their recommendations regarding the use of intravenous azithromycin. Azithromycin 1000 mg given orally,

Clinical Infectious Diseases® 2021;73(1):172–4

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.